SI-BONE Inc expected to post a loss of 13 cents a share - Earnings Preview
SI-BONE Inc (SIBN) is anticipated to report a loss of 13 cents per share, according to a Reuters earnings preview. This forecast provides an outlook on the company's financial performance. The article is a brief financial news item from Refinitiv.
A Look Ahead: SI-BONE's Earnings Forecast
SI-BONE (NASDAQ: SIBN) is scheduled to release its quarterly earnings report on Monday, February 23, 2026. Analysts project an EPS of $-0.13 for the company. Historically, positive earnings have led to a stock price increase, though shares are currently down 10.79% over the past year.
Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 93,475 Shares of Stock
SiBone (NASDAQ:SIBN) CEO Laura Francis sold 93,475 shares of company stock for approximately $1.43 million on February 17th, reducing her stake by 14.65%. Following the sale, shares traded up about 3.2% to $15.74. Analysts currently rate SiBone as a "Moderate Buy" with an average price target of $24.33, and institutional ownership remains very high at around 98%.
SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 20,756 Shares
SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 20,756 shares of SiBone stock on February 17th, with the transaction valued at $318,604.60. Following the sale, Pisetsky now owns 285,974 shares worth approximately $4,389,700.90, marking a 6.77% reduction in his stake. SiBone's stock traded up 3.2% to $15.74, and analysts maintain a "Moderate Buy" rating with an average target price of $24.33.
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, where management will host a fireside chat. The event will be available via webcast for investors. SI-BONE specializes in procedural solutions for compromised bone and has a strong clinical evidence base supporting its technologies.
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. (Nasdaq: SIBN), a leader in procedural solutions for compromised bone, announced its participation in the TD Cowen 46th Annual Health Care Conference. Management will host a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time/10:30 a.m. Eastern Time. The company has supported over 140,000 procedures since 2009, with its technologies backed by extensive clinical evidence.
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. (Nasdaq: SIBN), a global leader in procedural solutions for compromised bone, announced its participation in the TD Cowen 46th Annual Health Care Conference. Management will host a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time/10:30 a.m. Eastern Time. The company specializes in biomechanical design and innovation for spinopelvic anatomy, leveraging its expertise to develop new technologies and has supported over 140,000 procedures since 2009.
Earnings Preview: Si-Bone (SIBN) Q4 Earnings Expected to Decline
Si-Bone (SIBN) is projected to report a year-over-year decline in Q4 earnings despite higher revenues, with the report expected on February 23. Analysts anticipate a quarterly loss of $0.13 per share and revenues of $56.3 million. The company's Earnings ESP is 0%, and with a Zacks Rank #3, it is difficult to conclusively predict an earnings beat.
SiBone (SIBN) to Release Quarterly Earnings on Monday
SiBone (NASDAQ: SIBN) is scheduled to release its Q4 2025 earnings after market close on Monday, February 23, 2026. Analysts project an EPS of ($0.13) and revenue of approximately $56.26 million. Recent insider selling has occurred, with the CEO and CFO disposing of shares, while institutional investors have adjusted their holdings. The stock currently holds a "Moderate Buy" consensus rating with an average target price of $24.33 among brokerages.
SiBone (NASDAQ:SIBN) Receives Consensus Rating of "Moderate Buy" from Analysts
SiBone (NASDAQ: SIBN) has received a consensus "Moderate Buy" rating from seven analysts, with an average 12-month price target of $24.33. Recent insider selling by the CFO and CEO totaled approximately $2.34 million over the last 90 days, with insiders owning about 4% of the company. SiBone has a market capitalization of $665 million, a negative P/E ratio, and institutional ownership of nearly 98%.
Impax Asset Management Group plc Increases Stake in SiBone $SIBN
Impax Asset Management Group plc has significantly increased its stake in SiBone (NASDAQ:SIBN) by 48.2% in the third quarter, now owning 2.38% of the company's stock valued at over $15 million. Other institutional investors have also adjusted their positions in SiBone, with hedge funds and institutional investors collectively owning 98.11% of the company's stock. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus rating for SiBone with an average target price of $24.33, following the company's better-than-expected Q3 earnings and revenue.
SI-BONE, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2025, on February 23, 2026, after market close, followed by a conference call at 1:30 PM PT. The company specializes in procedural solutions for compromised bone, with significant clinical evidence and over 140,000 procedures since 2009. The announcement will provide transparency to investors and an opportunity for engagement with management.
Avoiding Lag: Real-Time Signals in (SIBN) Movement
This article provides an in-depth AI-driven analysis of Si-bone Inc. (NASDAQ: SIBN), highlighting weak near- and mid-term sentiment despite a positive long-term outlook. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report emphasizes the exceptional 63.2:1 risk-reward setup, targeting a 16.4% gain against 0.3% risk.
SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. announced it will report its fourth-quarter and full-year 2025 financial results on Monday, February 23, 2026, after market close. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for investors, with details provided for registration and webcast access. The company is a global leader in procedural solutions for compromised bone, with significant expertise in additive manufacturing.
SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. announced it will release its fourth-quarter and full-year 2025 financial results on Monday, February 23, 2026, after the market closes. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for investors to discuss these results. SI-BONE specializes in developing procedural solutions for compromised bone, with expertise in SI joint fusion, adult spinal deformity, and pelvic trauma.
SI-BONE, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. (SIBN) will report its Q4 and full-year 2025 financial results on February 23, 2026, after market close, followed by a conference call. The company, a leader in procedural solutions for compromised bone, will provide updates on its financial performance and operations. Investors can register online to access the call, which will also be webcast live on the company's website.
SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. announced it will release its financial results for the fourth quarter and full year ending December 31, 2025, on Monday, February 23, 2026, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for investors to listen to the webcast. SI-BONE is a global leader in developing procedural solutions for compromised bone, with expertise in additive manufacturing.
Y Intercept Hong Kong Ltd Grows Stake in SiBone $SIBN
Y Intercept Hong Kong Ltd significantly increased its holdings in SiBone (NASDAQ:SIBN) by 337.7% in Q3, now owning 83,369 shares valued at $1.23 million. Despite insiders being net sellers of the stock, offloading nearly $4 million worth of shares, analysts maintain a "Moderate Buy" rating with an average target price of $24.33. SiBone recently reported better-than-expected revenue of $48.66 million, though it remains unprofitable.
TD Cowen Initiates Coverage on SI-BONE (SIBN) with a 'Buy' Ratin
TD Cowen has initiated coverage on SI-BONE (SIBN) with a 'Buy' rating and a price target of $21.00 USD. This comes after several other analysts maintained 'Buy' or 'Overweight' ratings and raised price targets for SIBN in late 2025. The consensus among 9 analysts gives an average target price of $25.89, implying a potential upside of 51.04% from its current price, and suggesting an "Outperform" status.
A Glimpse Into The Expert Outlook On SI-BONE Through 5 Analysts
Five analysts have recently provided ratings for SI-BONE (NASDAQ: SIBN), predominantly bullish, setting an average 12-month price target of $24.2, an increase of 6.37% from the previous average. The company shows strong financial performance in revenue growth, net margin, and return on equity despite a smaller market capitalization. This article breaks down individual analyst actions and key financial indicators for SI-BONE.
TD Cowen initiates coverage on SI-BONE stock with Buy rating
TD Cowen initiated coverage on SI-BONE Inc. (NASDAQ:SIBN) with a Buy rating and a $21.00 price target, highlighting the company's unique focus on sacropelvic anatomy and a capital-light business model. The firm noted SI-BONE's strong revenue growth, robust gross profit margin, and positive trajectory towards profitability, expressing confidence that the company will exceed Street estimates. This positive outlook is supported by recent strong preliminary Q4 2025 revenue results and increased price targets from other analysts like Needham and Cantor Fitzgerald.
Discipline and Rules-Based Execution in SIBN Response
This article analyzes Si-bone Inc. (NASDAQ: SIBN), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It details a high risk-reward short setup and provides specific institutional trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis. The piece emphasizes the importance of discipline and rules-based execution in response to these AI-generated signals for SIBN.
SiBone (NASDAQ:SIBN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
SiBone (NASDAQ:SIBN) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $25.00. While the company recently beat revenue and EPS estimates, it remains unprofitable, and analysts project a negative EPS for the current fiscal year. Insider selling has occurred, but institutional investors hold a significant majority of the stock.
Further Weakness as SI-BONE (NASDAQ:SIBN) Drops 12% This Week, Taking Five-year Losses to 39%
SI-BONE Inc. (NASDAQ:SIBN) shares have dropped 12% this week, extending its five-year loss to 39%, despite a recent 17% gain over the last three months. The company, which is currently loss-making, has shown strong revenue growth of 20% per year over the past five years. Analysts suggest that the market has been harsh on the stock, given its top-line growth.
Behavioral Patterns of SIBN and Institutional Flows
This article provides an AI-driven analysis of Si-bone Inc. (NASDAQ: SIBN), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, and details multi-timeframe signal analysis for support and resistance. The report also offers access to real-time signals and personalized dashboard features for tracking the stock.
Dunn (SI-Bone director) sells $425k in SIBN stock
Jeffrey W. Dunn, a director at SI-Bone, Inc. (NASDAQ:SIBN), sold 20,000 shares of the company's common stock for over $425,000. This sale, executed via a 10b5-1 trading plan, occurred near the stock's 52-week high after a strong performance. The company recently reported robust preliminary Q4 2025 revenues and has received positive analyst ratings and price target increases from Needham and Cantor Fitzgerald.
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH)
Analysts have provided insights on several healthcare companies, including Incyte (INCY), SI-Bone (SIBN), and Guardant Health (GH). RBC Capital maintained a Hold rating for Incyte, while Needham and Jefferies reiterated Buy ratings for SI-Bone. Morgan Stanley and Bank of America Securities also maintained Buy ratings for Guardant Health, with all analyses including specific price targets and potential upsides or downsides.
Jim Cramer on SI-BONE: "This is a great, great speculation"
The article reports on Jim Cramer's positive remarks about SI-BONE (SIBH), calling it a "great, great speculation." This suggests Cramer sees significant upside potential for the company and is recommending it to investors as a speculative buy.
Press Release: SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE announced preliminary revenue for the fourth quarter and full year 2025. This press release indicates that Unity Software (U.US) reported a 35% year-over-year revenue increase to $609 million for Q4, surpassing the consensus estimate, despite reporting a quarterly loss of 66 cents per share. The article mentions that Dow Jones news is restricted due to copyright.
Dunn (SI-Bone director) sells $425k in SIBN stock By Investing.com
Jeffrey W. Dunn, a director at SI-Bone, Inc. (NASDAQ:SIBN), sold 20,000 shares of company stock for over $425,000. This sale occurred near the stock's 52-week high, following a significant 49% price increase over the last year. Despite the insider sale, SI-Bone maintains a strong financial profile, with recent positive preliminary revenue figures and optimistic analyst ratings from Needham and Cantor Fitzgerald.
Dunn (SI-Bone director) sells $425k in SIBN stock By Investing.com
Jeffrey W. Dunn, a director at SI-Bone, Inc. (NASDAQ:SIBN), sold 20,000 shares of the company's stock for over $425,000. This sale occurred near the stock's 52-week high after a strong performance, and was executed under a 10b5-1 trading plan. The company shows positive financial indicators and recent analyst upgrades, with its next earnings report due in March 2026.
Dunn (SI-Bone director) sells $425k in SIBN stock By Investing.com
Jeffrey W. Dunn, a director at SI-Bone, Inc. (NASDAQ:SIBN), sold 20,000 shares of company stock for over $425,000 on January 8, 2026, at an average price of $21.2753. This sale occurred near the stock's 52-week high, following a substantial 49% price increase over the last year. Despite the insider sale, analysts maintain a positive outlook on SI-Bone, with Needham and Cantor Fitzgerald reiterating Buy and Overweight ratings, respectively, based on strong revenue growth and earnings performance.
SI-BONE Reports Strong Preliminary Q4 and 2025 Revenue Growth
SI-BONE (SIBN) announced strong preliminary results for Q4 and full-year 2025, with worldwide revenue growing about 15% and 20% respectively. The company saw an 18% increase in active U.S. physicians and achieved positive cash generation in the fourth quarter. While an analyst maintains a Buy rating, TipRanks' AI Analyst Spark rates SIBN as Neutral due to ongoing profitability and cash flow concerns despite strong revenue growth.
SI-BONE, Inc. Reports Preliminary Fourth Quarter and Full Year 2025 Revenue Growth
SI-BONE, Inc. announced preliminary unaudited revenue and cash figures for Q4 and full year 2025, reporting significant year-over-year growth. For Q4 2025, worldwide revenue is estimated between $56.2 - $56.3 million (15% growth), and for the full year 2025, it's projected between $200.8 - $200.9 million (20% growth). The company also noted an increase in active U.S. physicians and a strong cash position.
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE, Inc. announced preliminary and unaudited revenue figures for the fourth quarter and full year 2025. The company projects worldwide revenue between $56.2 - $56.3 million for Q4 2025, representing approximately 15% growth, and between $200.8 - $200.9 million for the full fiscal year 2025, a growth of about 20%. These figures are subject to adjustment pending the completion of financial closing procedures and an audit by external auditors.
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE, Inc. announced preliminary unaudited revenue and cash equivalents for the fourth quarter and full fiscal year 2025. The company expects worldwide revenue of $56.2-$56.3 million for Q4 2025 and $200.8-$200.9 million for the full fiscal year 2025, representing approximately 15% and 20% growth, respectively. These figures are subject to adjustment pending completion of financial closing procedures and audit.
Lobbying Update: $10,000 of SI-BONE INC. lobbying was just disclosed
SI-BONE INC. (SIBN) recently disclosed $10,000 in lobbying activity for Q4 2025, focusing on medical device industry issues and reimbursement for implantable devices. This disclosure comes alongside significant insider selling of SIBN stock and mixed hedge fund activity, with a median analyst price target of $25.0 from five analysts.
Jim Cramer on SI-BONE: "This is a Great, Great Speculation"
Jim Cramer commented on SI-BONE (SIBN), calling it a "great, great speculation" during a lightning round. He expressed keen interest in researching the company further with his director, Ben Stoto. SI-BONE develops medical devices for musculoskeletal disorders in the sacropelvic area.
Jim Cramer on SI-BONE: “This is a Great, Great Speculation”
Jim Cramer commented on SI-BONE, Inc. (NASDAQ: SIBN), calling it a "great speculation" and expressing his intent to research the company further due to its frequent mentions. SI-BONE develops and sells medical devices for musculoskeletal disorders, including minimally invasive implants for sacroiliac joint dysfunction. The article, however, suggests that alternative AI stocks might offer greater return potential.
Jim Cramer on SI-BONE: “This is a Great, Great Speculation”
Jim Cramer commented on SI-BONE, Inc. (SIBN) during a lightning round, calling it a "great, great speculation" and noting he hears the company's name frequently. SI-BONE develops medical devices for musculoskeletal disorders in the sacropelvic area. The article suggests that while SIBN holds potential, certain AI stocks might offer better upside and less risk.
Jim Cramer on SI-BONE: “This is a Great, Great Speculation”
Jim Cramer commented on SI-BONE, Inc. (SIBN), calling it a "great speculation" and stating he would delve deeper into the company with his research director. SI-BONE develops medical devices for musculoskeletal disorders in the sacropelvic area. The article, however, suggests that certain AI stocks might offer greater upside potential with less risk than SIBN.
Why Did SI-Bone (SIBN) Surge Spike After Hours?
SI-Bone Inc. (SIBN) shares surged 3.65% in after-hours trading on Tuesday, closing at $21.14. This increase occurred despite recent sales by three executives to cover tax obligations from restricted stock unit vesting. Analysts from Truist Securities, Canaccord Genuity, Needham & Company, and Morgan Stanley maintained bullish stances and raised price targets for SIBN.
Calamos Advisors LLC Sells 65,184 Shares of SiBone $SIBN
Calamos Advisors LLC reduced its stake in SiBone (NASDAQ:SIBN) by 86.7% in the third quarter, selling 65,184 shares and retaining 10,019 shares valued at $147,000. Despite significant insider selling over the past 90 days, analysts largely maintain bullish ratings with an average target price of $25. The company's financials include a market capitalization of $858.71 million and an EPS of ($0.11) for the last quarter.
(SIBN) Movement Within Algorithmic Entry Frameworks
Si-bone Inc. (NASDAQ: SIBN) is exhibiting conflicting sentiment across horizons, indicating choppy conditions with a mid-channel oscillation pattern. The article presents various algorithmic entry frameworks, including a strong short setup with a 43.0:1 risk-reward ratio, alongside long (position trading) and momentum breakout strategies. Multi-timeframe signal analysis reveals varying support and resistance levels across near, mid, and long-term horizons, suggesting complex trading opportunities.
Assenagon Asset Management S.A. Invests $3.30 Million in SiBone $SIBN
Assenagon Asset Management S.A. has invested $3.30 million in SiBone (NASDAQ:SIBN) by acquiring 224,004 shares in Q3, representing a 0.52% stake in the company. This investment comes amidst significant insider selling, yet analyst sentiment remains positive with a "Moderate Buy" consensus and a $25 price target. SiBone also surpassed Q3 revenue and EPS estimates, with its stock currently trading near $20.81.
Insider Sell: Michael Pisetsky Sells 19,600 Shares of SI-BONE In
Michael Pisetsky, Senior Vice President at SI-BONE Inc (SIBN), sold 19,600 shares of the company on December 18, 2025, reducing his holdings to 231,896 shares. This transaction is part of a trend for SIBN, which has seen 46 insider sells and no insider buys over the past year. Shares were trading at $20.15, indicating the stock is fairly valued relative to its GF Value of $20.09.
SI-BONE (NASDAQ:SIBN) increases 8.9% this week, taking three-year gains to 71%
SI-BONE Inc. (NASDAQ:SIBN) has seen its share price increase by 8.9% this week, contributing to a 71% gain over the past three years, although this is below the broader market return. The company, which is not yet profitable, has demonstrated strong revenue growth of 21% annually over the last three years. While recent returns for shareholders have been positive at 53% over the last year, the long-term five-year performance shows a 6% annual loss.
Some Shareholders Feeling Restless Over SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Ratio
SI-BONE, Inc.'s stock currently has a P/S ratio of 4.5x, which is higher than nearly half of its industry peers, but its strong recent revenue growth of 23% might justify this. However, future revenue growth is projected to be only 15% annually, significantly lower than the industry's 121% forecast, leading to concerns that the current P/S ratio might be unsustainable. This disparity suggests that investors are banking on a turnaround not supported by analyst predictions, potentially putting shareholders at risk.
SI-BONE (NASDAQ:SIBN) increases 8.9% this week, taking three-year gains to 71%
SI-BONE (NASDAQ:SIBN) shares have increased by 8.9% this week, contributing to a 71% gain over the past three years, although this is below the broader market return. The company, which is not yet profitable, has shown strong revenue growth of 21% annually over the last three years. Shareholders have seen a 53% total return in the last year, suggesting a potentially brighter future despite a long-term loss over five years.
SI-BONE (NASDAQ:SIBN) increases 8.9% this week, taking three-year gains to 71%
SI-BONE Inc. (NASDAQ:SIBN) experienced an 8.9% increase in its stock price this week, contributing to a 71% gain over three years, though this is still below average market returns. The company, which is not yet profitable, has shown strong revenue growth of 21% annually over the last three years. Despite recent positive short-term returns of 53% over the last year, its long-term performance over five years has been a 6% annual loss, prompting closer examination of its fundamentals.
